Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder
| Autor: | David C. Henderson, Katlyn L. Nemani, Paul M. Copeland, Melissa Ulloa, Sulaiman Al-Khadari, Brenda Vincenzi, M. Claire Greene |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Schizoaffective disorder Disease Article 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Diabetes mellitus Diabetes Mellitus medicine Humans Psychiatry Clozapine medicine.diagnostic_test business.industry Medical record General Medicine medicine.disease 030227 psychiatry Psychiatry and Mental health Psychotic Disorders Cardiovascular Diseases Schizophrenia Smoking cessation Female Lipid profile business 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Clinical Schizophrenia & Related Psychoses. 12:168-176 |
| ISSN: | 1935-1232 |
| DOI: | 10.3371/csrp.knmg.111717 |
| Popis: | The goal of this 21-year naturalistic study of clozapine-treated patients was to examine the cardiovascular risk factors following clozapine initiation and resultant mortality estimates from cardiovascular disease. Data were collected from January 1992 to February 2012 medical records from clozapine-treated patients with schizophrenia or schizoaffective disorder. Demographics, clozapine dosage and laboratory results were extracted at 12-month intervals. At clozapine initiation, the mean age of the 96 patients was 36.4 years±7.6 years; n=27 (28%) were women. The mean duration of clozapine use was 13 years. The Kaplan-Meier estimate for 21-year cardiovascular events was 29%, while the Kaplan-Meier estimate for 21-year mortality from cardiovascular disease was 10%. The mean cardiovascular risk increased during the first ten years (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|